Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors.
Dimitra DimopoulouNikos SpyridisGeorge VartzelisMaria N TsoliaDespoina N MaritsiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Patients with rheumatic and musculoskeletal diseases (RMDs) on immunosuppressants are considered a vulnerable group in COVID-19 pandemic and vaccination is the mainstay for the prevention of this infection (1). To date, recommendations and data for COVID-19 vaccination in adolescent patients with RMDs are lacking (2). International societies and post-authorization safety reports of the novel mRNA COVID-19 vaccines are generally reassuring; nonetheless their safely profile in adolescents with RMDs on immune-modulating treatment is unknown, since these individuals were excluded from the vaccine trials (3-5).
Keyphrases
- coronavirus disease
- sars cov
- young adults
- juvenile idiopathic arthritis
- rheumatoid arthritis
- physical activity
- mental health
- emergency department
- randomized controlled trial
- respiratory syndrome coronavirus
- machine learning
- clinical practice
- open label
- systemic lupus erythematosus
- disease activity
- study protocol
- electronic health record
- combination therapy
- deep learning
- big data
- replacement therapy
- adverse drug